Patient with neuromyelitis optica and inflammatory demyelinating lesions comprising whole spinal cord from C2 level till conus: case report
© Petelin Gadze et al; licensee BioMed Central Ltd. 2009
Received: 28 May 2009
Accepted: 23 October 2009
Published: 23 October 2009
Neuromyelitis optica (NMO) is an idiopathic, severe, inflammatory demyelinating disease of the central nervous system, that causes severe optic neuritis and myelitis attacks. Early discrimination between multiple sclerosis (MS) and NMO is important, as optimum treatment for both diseases may differ considerably.
We report a case of a patient who initially presented as longitudinally extensive transverse myelitis (LETM), having spastic upper extremities diparesis and spastic paraplegia, C2/C3 sensory level and urinary incontinence, as well as extensive inflammatory spinal cord lesions from C2 level to conus. After 5 months the patient had another attack of transverse myelitis, had electrophysiological findings consistent with optic neuritis, was seropositive for NMO-IgG (aquaporin-4 IgG) and thus fulfilled NMO diagnostic criteria. Following treatment of disease attacks with pulse corticosteroid therapy and intravenous immunoglobulins, we included oral azathioprine in a combination with oral prednisone in the therapy. Since there was no significant clinical improvement, we decided to use cyclophosphamide therapy, which resulted in good clinical improvement and gradual decrease of cord swelling.
In this NMO case report we wanted to emphasize the extensiveness of inflammatory spinal cord changes in our patient, from C2 level to conus. In the conclusion it is important to say that accurate, early diagnosis and distinction from MS is critical to facilitate initiation of immunosuppressive therapy for attack prevention.
Neuromyelitis optica (NMO) or Devic's syndrome is an idiopathic, severe, inflammatory demyelinating disease of the central nervous system that selectively affects optic nerves and spinal cord. It tends to spare the brain early in the disease course. Early discrimination between multiple sclerosis (MS) and NMO is important, as optimum treatment for both diseases may differ considerably. In contrast to typical MS, clinical experience and case series suggest that NMO requires long-term immunosuppressive therapy. Diagnostic criteria for NMO from 1999 have been revised in 2006 by Wingerchuk et al. Diagnosis requires absolute criteria and at least two of three supportive criteria. Absolute criteria include presence of optic neuritis and acute myelitis, and supportive criteria negative brain magnetic resonance imaging (MRI) at disease onset, spinal cord MRI with contiguous T2-weighted signal abnormality based centrally in the cord and extending over 3 or more vertebral segments (LETM - longitudinally extensive transverse myelitis), and NMO-IgG (aquaporin-4 IgG) seropositive status [1, 2]. NMO-IgG has facilitated an appreciation that the spectrum of NMO is wider than previously recognized, and includes patients with recurrent longitudinally extensive transverse myelitis, recurrent isolated optic neuritis, and Japanese opticospinal MS . A variety of encephalopathic presentations may occasionally be encountered in NMO-IgG seropositive patients, most commonly in children .
In this article we report a case of a patient who initially presented as LETM, having spastic upper extremities diparesis and spastic paraplegia, C2/C3 sensory level and urinary incontinence, as well as extensive inflammatory spinal cord lesions from C2 level to conus. After 5 months LETM evolved to neuromyelitis optica.
Patient A.V., Caucasian, born in 1966, with a history of rhematic fever at the age of 8, in May 2006 was operated in another institution due to left paramedian L5-S1 disc herniation, which clinically presented with plegia of the left leg, pain and hypoesthesia in the left L5 - S1 dermatome, and urinary incontinence. After operation and physical rehabilitation her neurological status improved. However, at the beginning of August 2006, motor weakness of the left leg worsened, and was accompanied by development of weakness of the right leg. In a few days she became paraplegic with Th4 sensory level and urinary incontinence. MRI of the thoracal spinal cord revealed edematous enlargement extending from Th4 to Th6 level, suspect of expansive process, but during second operation 5 cm long arachnoid cyst was revealed and neurosurgeons performed fenestration of the cyst. Soon after she was sent to physical rehabilitation. In the next few months her condition slightly improved, she again began to walk, with assistance (crutches). In December 2006 her neurological status again started to deteriorate, in the next few months weakness of legs worsened, and she also developed weakness of both arms, accompanied with paresthesiae and dysesthesiae in arms and legs.
After 5 months she again progressively developed weakness, paresthesiae and dysesthesiae in arms, more pronounced in the left arm, as well as transitory blurring of vision on both eyes. Control MRI of the spinal cord revealed progression of extensive demyelinating lesions in the cervical segment. Repeated brain MRI was normal. Control VEP revealed conduction disturbances (prolonged latencies) in both optic pathways. In the meantime, we have received positive finding of NMO-IgG antibodies from Mayo Medical Laboratories. According to that finding, clinical presentation and MRI finding we made the diagnosis neuromyelitis optica. Patient was again treated with intravenous methylprednisolone and IVIGs, that resulted in minimal clinical improvement of weakness in upper extremities, but there was no improvement of spastica paraplegia. She remained restricted to bed. In the following months we also included oral azathioprine in a combination with oral prednisone in the therapy, but since there was no significant clinical improvement, we considered other treatment modalities. In January 2008 we started treatment with intravenous cyclophosphamide (1 g/m2) in a combination with methylprednisolone (1000 mg), once a month during six months. Partial remission of disease activity has been achieved. At the moment patient can use both her arms and can stand supported by sticks. Her recent MRI of the spinal cord revealed gradual decrease of cord swelling and T2 signal hyperintensity. In the meantime, following steroid therapy, she developed diabetes mellitus and osteoporosis, that are being treated successfully.
Written informed consent was obtained from the patient for publication of this case report and accompanying images. A copy of the written consent is available for review by the Editor-in-Chief of this journal.
Neuromyelitis optica (NMO) was first identified in the 19th century, as a monophasic, destructive disorder affecting the spinal cord and both optic nerves, but sparing the remainder of the central nervous system (CNS). The position of NMO within the group of CNS demyelinating diseases has been long debated - whether this clinical entity is a severe variant of MS, a form of acute disseminated encephalomyelitis, or a distinct disease [5, 6]. It has gradually become accepted that the spectrum of idiopathic NMO is broader than suggested by the historical definition. The recent discovery of serum autoantibody marker NMO-IgG in 2004 further advances the hypothesis that NMO is actually a distinct disease . NMO-IgG is 73% sensitive and 91% specific for distinguishing NMO from optic-spinal presentations of classical MS. The target antigen of NMO-IgG is aquaporin 4 (AQP4), glial water channel protein, that facilitates water transport, especially in "stress situations" such as brain injury. It is component of the dystroglycan protein complex located in astrocytic foot processes at the blood-brain barrier. Data suggest that autoantibodies to aquaporin 4, derived from peripheral B cells, cause the activation of complement, inflammatory demyelination, and necrosis that is seen in neuromyelitis optica [7, 8]. It is also important to emphasize that patients presenting with a first-ever LETM event, who are found to be NMO-IgG seropositive, have a 56% risk of LETM recurrence or optic neuritis (conversion to NMO) during the subsequent 12 months . With the positive NMO-IgG finding we confirmed the diagnosis of NMO in our patient, who satisfied all absolute and supportive diagnostic criteria .
According to the data from the literature, most patients with NMO, perhaps more than 90%, have relapsing rather than monophasic disease , which was also the case in our patient, but was not recognized as that in the beginning of the disease. Our patient met the features of relapsing NMO, such as female dominance, older age at onset, and probably autoimmune disease - we could assume that steroid therapy unmasked autoimmune diabetes mellitus .
For many neurologists, the current standard preventive approach for NMO includes oral azathioprine in a combination with oral prednisone, rituximab (chimeric anti-CD20 monoclonal antibody), mitoxantrone, IVIGs, and cyclophosphamide [11–17]. The best evidence (although all from retrospective series) for long-term immunosuppression in NMO is with azathioprine and rituximab, that are considered first line therapies, while cyclophosphamide is generally considered as a second line agent in NMO. In a recently published retrospective multicenter case series of NMO patients treated with rituximab, that included 25 patients (including 2 children), 23 of whom experienced relapses despite use of other drugs before rituximab, treatment with rituximab appeared to reduce the frequency of attacks, with subsequent stabilization or improvement in disability. Jarius et al reported that treatment with immunosuppressants such as rituximab, azathioprine and cyclophosphamide resulted in a marked reduction in antibody levels as well as in relapse rates, demonstrating a strong relationship between AQP4-Abs and clinical state. Cyclophosphamide resulted in a long-lasting relapse-free interval in one of their patients, with 10 relapses within 1295 days (2.82/year) prior to initiation of therapy but only one within 1610 days (0.23/year) under therapy . Immunoablative cyclophosphamide was also successful in halting relapses in a patient with systemic lupus erythematosus-associated NMO who was unresponsive to high-dose oral and intravenous corticosteroids, intravenous immunoglobulin, mycophenolate mofetil, tacrolimus, low-dose daily oral cyclophosphamide and rituximab .
After treating diseases attacks with pulse corticosteroid therapy and IVIGs in our patient, we included oral azathioprine in a combination with oral prednisone in the therapy, but since there was no significant therapeutic response, we decided to use cyclophosphamide therapy. That resulted in good clinical improvement and gradual decrease in cord swelling and T2 signal hyperintensity. We were also considering to use rituximab, but at that time this agent was not approved for treating NMO in Croatia.
It is important to point out that one does not need to wait for a second attack of transverse myelitis or optic neuritis prior to commencing immunosuppression if NMO-IgG is positive, since NMO-IgG itself predicts a relapsing course. Unfortunately, at the time we received positive finding of NMO-IgG antibodies from Mayo Clinic, our patient experienced relapse. If immunosuppresive therapy had been started earlier in the course of the disease (patient's clinical worsening started to happen one year before admission to our institution), maybe the prognosis for this patient could be more favourable.
In this case report we wanted to emphasize the extensiveness of inflammatory spinal cord changes in our patient, from C2 level to conus, which was initially attributed to LETM, but after some time evolved to neuromyelitis optica. In the conclusion it is important to say that accurate, early diagnosis and distinction from multiple sclerosis is critical to facilitate initiation of immunosuppressive therapy for attack prevention.
We would like to thank Dr. Davorka Milat, radiologist (Head Assistant of the Polyclinic Sunce, Zagreb), for her support and help in preparing MR images for this article.
- Wingerchuk DM, Lennon VA, Pittock SJ, Lucchinetti CF, Weinshenker BG: Revised diagnostic criteria for neuromyelitis optica. Neurology. 2006, 66 (10): 1485-9. 10.1212/01.wnl.0000216139.44259.74.View ArticlePubMedGoogle Scholar
- Wingerchuk DM, Weinshenker BG: Neuromyelitis optica. Curr Treat Options Neurol. 2008, 10 (1): 55-66. 10.1007/s11940-008-0007-z.View ArticlePubMedGoogle Scholar
- Lennon VA, Wingerchuk DM, Kryzer TJ, Pittock SJ, Lucchinetti CF, Fujihara K, Nakashima I, Weinshenker BG: A serum autoantibody marker of neuromyelitis optica: distinction from multiple sclerosis. Lancet. 2004, 364 (9451): 2106-12. 10.1016/S0140-6736(04)17551-X.View ArticlePubMedGoogle Scholar
- McKeon A, Lennon VA, Lotze T, Tenenbaum S, Ness JM, Rensel M, Kuntz NL, Fryer JP, Homburger H, Hunter J, Weinshenker BG, Krecke K, Lucchinetti CF, Pittock SJ: CNS aquaporin-4 autoimmunity in children. Neurology. 2008, 71 (2): 93-100. 10.1212/01.wnl.0000314832.24682.c6.View ArticlePubMedGoogle Scholar
- Wingerchuk DM, Weinshenker BG: Neuromyelitis optica. Multiple Sclerosis. Edited by: McDonald WI, Noseworthy JH. 2003, Woburn, MA: Butterworth-Heinemann, 243-58. 2Google Scholar
- Pittock SJ, Lennon VA, Krecke K, Wingerchuk DM, Lucchinetti CF, Weinshenker BG: Brain abnormalities in neuromyelitis optica. Arch Neurol. 2006, 63 (3): 390-6. 10.1001/archneur.63.3.390.View ArticlePubMedGoogle Scholar
- Takahashi T, Fujihara K, Nakashima I, Misu T, Miyazawa I, Nakamura M, Watanabe S, Shiga Y, Kanaoka C, Fujimori J, Sato S, Itoyama Y: Anti-aquaporin 4 antibody is involved in the pathogenesis of NMO: a study on antibody titre. Brain. 2007, 130: 1235-43. 10.1093/brain/awm062.View ArticlePubMedGoogle Scholar
- Wingerchuk DM, Lennon VA, Lucchinetti CF, Pittock SJ, Weinshenker BG: The spectrum of neuromyelitis optica. Lancet Neurol. 2007, 6 (9): 805-15. 10.1016/S1474-4422(07)70216-8.View ArticlePubMedGoogle Scholar
- Wingerchuck DM: Diagnosis and Treatment of Neuromyelitis Optica. Neurologist. 2007, 13: 2-11. 10.1097/01.nrl.0000250927.21903.f8.View ArticleGoogle Scholar
- Wingerchuck DM, Hogancamp WF, O'Brien PC, Weinshenker BG: The clinical course of neuromyelitis optica (Devic's syndrome). Neurology. 1999, 53: 1107-14.View ArticleGoogle Scholar
- Mandler RN, Ahmed W, Dencoff JE: Devic's neuromyelitis optica: a prospective study of seven patients treated with prednisone and azathioprine. Neurology. 1998, 51: 1219-20.View ArticlePubMedGoogle Scholar
- Birnbaum J, Kerr D: Optic neuritis and recurrent myelitis in a woman with systemic lupus erythematosus. Nat Clin Pract Rheumatol. 2008, 4 (7): 381-6.PubMedGoogle Scholar
- Feingold RM: Neuromyelitis optica. J Insur Med. 2008, 40 (2): 136-40.PubMedGoogle Scholar
- Jacob A, Weinshenker BG, Violich I, McLinskey N, Krupp L, Fox RJ, Wingerchuk DM, Boggild M, Constantinescu CS, Miller A, De Angelis T, Matiello M, Cree BA: Treatment of neuromyelitis optica with rituximab: retrospective analysis of 25 patients. Arch Neurol. 2008, 65 (11): 1443-8. 10.1001/archneur.65.11.noc80069.View ArticlePubMedGoogle Scholar
- Jarius S, Aboul-Enein F, Waters P, Kuenz B, Hauser A, Berger T, Lang W, Reindl M, Vincent A, Kristoferitsch W: Antibody to aquaporin 4 in the long-term course of neuromyelitis optica. Brain. 2008, 131: 3072-80. 10.1093/brain/awn240.View ArticlePubMedPubMed CentralGoogle Scholar
- Schröder A, Ellrichmann G, Chehab G, Schneider M, Linker RA, Gold R: Rituximab in treatment for neuroimmunological diseases. Nervenarzt. 2009, 80 (2): 155-65. 10.1007/s00115-008-2663-3.View ArticlePubMedGoogle Scholar
- Mok CC, To CH, Mak A, Poon WL: Immunoablative cyclophosphamide for refractory lupus-related neuromyelitis optica. J Rheumatol. 2008, 35 (1): 172-4.PubMedGoogle Scholar
- The pre-publication history for this paper can be accessed here:http://www.biomedcentral.com/1471-2377/9/56/prepub
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.